GET DAILY SIGNALSWerewolf Therapeutics (HOWL): The Road to +308% Upside from Current Levels
Key Takeaways
- The central HOWL price target used here is $4.00, the arithmetic mean of the verified, current analyst price targets reviewed.
- The stock last traded near $0.98, so reaching $4.00 would require roughly 308% upside — a very large move.
- The verified target range is wide, from $1.00 (Wedbush) to $7.00 (B of A Securities), with H.C. Wainwright at $4.00, reflecting deep disagreement about the pipeline's prospects.
- The strongest supporting factors are a promising oncology pipeline and a collaboration with Jazz Pharmaceuticals, while the biggest risks are clinical-stage status, heavy cash burn, and a wave of late-2025 downgrades.
- You can find more on this ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
Analyst Price Targets and Consensus View
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) is a clinical-stage biopharmaceutical company that uses its PREDATOR platform to develop "INDUKINE" molecules — conditionally activated cytokines designed to stimulate the immune system against cancer while limiting off-target toxicity. The company is headquartered in Watertown, Massachusetts.
For this analysis, the central target is the arithmetic mean of the verified, current analyst price targets. Roughly four analysts currently publish a 12-month price target, according to TipRanks and MarketBeat. The clearly attributable figures cluster as follows: Wedbush at $1.00 (downgraded to Neutral in December 2025), H.C. Wainwright at $4.00 (Buy, reduced from $10.00), and B of A Securities at $7.00 (Buy, reduced from $8.00). Averaging these verified targets yields a mean of approximately $4.00, which serves as the central target throughout this article. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The $1.00-to-$7.00 spread is unusually wide and reflects sharply divided views. Bulls, represented by H.C. Wainwright and B of A Securities, emphasize the potential of lead programs WTX-124 and WTX-330. More cautious analysts, including Wedbush and Citigroup, which downgraded the stock to Market Perform in December 2025, cite limited near-term catalysts and financing risk. The mean of $4.00 should be read as a midpoint of disagreement, not a consensus forecast or a guarantee.
Current Market Position and Path Toward the Target
HOWL shares recently traded around $0.98, near the low end of a 52-week range spanning roughly $0.27 to $2.38. Moving to the $4.00 central target would require an increase of about 308%, which must be described as a very large move. For a pre-commercial biotech, such a move typically depends on clinical data readouts or a major partnership event rather than incremental operating progress.
The company's lead candidates are WTX-124, a conditionally activated IL-2 INDUKINE, and WTX-330, a conditionally activated IL-12 INDUKINE, both in development for advanced solid tumors and lymphoma. Werewolf also has a collaboration with Jazz Pharmaceuticals on JZP898, a conditionally activated interferon-alpha INDUKINE. This collaboration has generated modest revenue — roughly $1.9 million in 2024 versus $19.9 million in 2023 — meaning the company remains primarily dependent on clinical milestones and capital raises rather than product sales.
What Could Support a Move Toward the Target
Positive clinical data from WTX-124 or WTX-330 would be the most direct catalyst for re-rating the shares. Encouraging safety or efficacy signals in immuno-oncology can rapidly change sentiment for a sub-$1 stock, as seen historically across the sector. The Jazz Pharmaceuticals partnership also provides external validation of the PREDATOR platform and a source of milestone-driven, non-dilutive funding.
A stabilization or upward revision of analyst targets — several were sharply lowered in late 2025 — could also support the shares. Broader momentum in oncology and biotech, a favorable interest-rate environment for risk assets, and any improvement in the company's cash runway would further strengthen the case for a higher valuation.
What Could Prevent the Target From Being Reached
The principal risk is clinical failure or disappointing trial data, which is common in early-stage oncology and could push the stock materially lower. Werewolf is pre-revenue apart from modest collaboration income, meaning it is dependent on dilutive equity offerings that can pressure the share price. The stock's decline of roughly 45% over the past year, its proximity to 52-week lows, and the December 2025 downgrades by Wedbush, Citigroup, and Citizens JMP all point to eroding Street conviction.
Because the price target range is so wide — from $1.00 to $7.00 — even the $4.00 mean rests on assumptions about pipeline success that are far from assured. A prolonged biotech downturn, rising interest rates, or execution delays could all keep the stock well below the target.
Technical Levels and Market Structure
The $1.00 round-number level now acts as a key psychological pivot, with the stock trading just beneath it. On the downside, the 52-week low near $0.27 represents a distant support zone. On the upside, the 52-week high around $2.38 stands as a significant resistance area, meaning the stock would need to roughly double from current levels before even approaching the midpoint of its 52-week range — and nearly quadruple to reach the $4.00 target.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms may differ. Investors should monitor upcoming earnings reports, clinical data readouts for WTX-124 and WTX-330, any guidance or financing announcements, and revisions from the analysts noted above. Changes to the Jazz collaboration, regulatory updates, and broader biotech sector flows are also relevant to the outlook.
Final Assessment
The $4.00 central target is the arithmetic mean of verified analyst price targets, spanning $1.00 to $7.00 — a range that captures genuine uncertainty about Werewolf Therapeutics' clinical prospects. Reaching that level would require roughly 308% upside, an enormous move that hinges overwhelmingly on positive pipeline data and restored analyst confidence. Supportive factors include the PREDATOR platform and the Jazz collaboration; the principal obstacles are clinical risk, cash burn, dilution, and recent downgrades. Investors should focus next on clinical readouts, financing news, and any target revisions, while recognizing that the wide analyst range means the target is best viewed as a benchmark, not a forecast.
Using Tickeron’s AI Daily Buy/Sell Signals
In my own research process, Tickeron’s AI Daily Buy/Sell Signals have proven useful for tracking volatile names like this one. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and shifting market conditions. For a clinical-stage biotech, it helps separate short-term noise from the longer-term fundamentals that matter most to the analyst targets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HOWL sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for HOWL moved above the 200-day moving average on September 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on HOWL as a result. In 66 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +6.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where HOWL advanced for three days, in 201 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 118 of 137 cases where HOWL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for HOWL moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 23 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 54 cases where HOWL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for HOWL turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 38 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HOWL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
HOWL broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. HOWL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.102) is normal, around the industry mean (2.974). P/E Ratio (-1.444) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (2.169) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HOWL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement